Washington, DC – PPMD has provided $250,000 in funding to Rare Disease Research, LLC (RDR), to open a second independent rare disease clinical research site in the Raleigh-Durham metropolitan area in North Carolina. With this funding commitment, we aim to support RDR’s creation of an avenue that increases patient access...
Latest News
South Bend, Indiana – Adding a pre-ketone supplement — a component of a high-fat, low-carb ketogenic diet — to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers from the University of Notre Dame found. Recently published online in the journal Cancer...
Philadelphia, PA – Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus. The European Society of Medical Oncology is highlighting the trial at its ESMO...
GERMANTOWN, Md. – Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory...
GERMANTOWN, Md., March 18, 2021 — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS)...
Beijing, China – Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM...
Lund – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the company’s website. The data were presented at two poster presentations at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia. The results presented...
MEMPHIS, Tenn. – A study from St. Jude Children’s Research Hospital sheds light on the incidence of prediabetes and diabetes in childhood cancer survivors for better prevention and treatment. At a younger age, childhood cancer survivors can experience chronic conditions such as diabetes, typically associated with older individuals. Researchers found...
PITTSBURGH, PA – A new study indicates that severity of amyloid deposition in the brain — not just age — may be key to determining who will benefit from new anti-amyloid therapies to delay the progression of Alzheimer’s disease. University of Pittsburgh clinicians and scientists report that the accumulation of...
High-grade prostatic intraepithelial neoplasia (HGPIN) carries a high predictive value for future diagnosis of prostate cancer. Research published in the open access journal BMC Urology has shown that 41.8% of patients whose extended core biopsy led to an initial diagnosis of HGPIN were subsequently diagnosed with prostate cancer. Paras Singh...